Gerrit-Anne van Es

Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial

Stephan Windecker, Patrick W. Serruys, Simon Wandel et al. · The Lancet · 2008 · 652 citations

Medicine, Cardiology, Surgery +17

Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial

Marie-Claude Morice, Patrick W. Serruys, A. Pieter Kappetein et al. · Circulation · 2010 · 644 citations

Medicine, Cardiology, Surgery +13

Assessment of the SYNTAX score in the Syntax study

Patrick Serruys, Yoshinobu Onuma, Scot Garg et al. · EuroIntervention · 2009 · 643 citations

Medicine, Cardiology, Clinical Classification Systems +12

Effects of the Direct Lipoprotein-Associated Phospholipase A ₂ Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque

Patrick W. Serruys, Héctor M. García‐García, Paweł Buszman et al. · Circulation · 2008 · 505 citations · Full text

Medicine, Cardiology, Pharmacology +17

The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase

Andrew T.L. Ong, Patrick W. Serruys, Frederick W. Mohr et al. · American Heart Journal · 2006 · 337 citations

Medicine, Cardiology, Surgery +13